Trial reportEuropean radiology2020
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Trial report in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Microwave Ablation Combined With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer-Systematic Review and Meta-Analysis.Thoracic cancer · 2026Pooled it
- The efficacy and safety of thermal ablation for patients with lung malignancy: a meta-analysis of 12 studies in China.Journal of cardiothoracic surgery · 2022Pooled it
- A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy.European radiology · 2023Trial
- Research status and trend of lung cancer ablation therapy: a bibliometric analysis from 2002 to 2025.Journal of thoracic disease · 2026Article
- Microwave ablation combined with dendritic cells enhances CD8Cancer immunology, immunotherapy : CII · 2026Article
- Risk factors and immune landscape of early local tumor progression after microwave ablation for lung cancer: a retrospective nested case-control study.Frontiers in immunology · 2026Article
- Microwave ablation for residual ground-glass nodule-like lung cancer after video-assisted thoracoscopic surgery: a retrospective, large-sample, multicenter study.La Radiologia medica · 2026Article
- Local consolidative therapy extends survival in metastatic NSCLC with oligoresidual disease following first-line immunotherapy, irrespective of PD-L1 expression.Scientific reports · 2025Article
- Development of a predictive model for pneumothorax after microwave ablation based on radiomics and clinical baseline data.BMC pulmonary medicine · 2025Article
- Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.Thoracic cancer · 2025Article
- Review
- Microwave ablation combined with immune checkpoint inhibitor enhanced the antitumor immune activation and memory in rechallenged tumor mouse model.Cancer immunology, immunotherapy : CII · 2025Article
- Comparative safety and efficacy of single-agent chemotherapy combined with microwave ablation versus radioactive seed brachytherapy in elderly patients with advanced NSCLC: a ten-year retrospective study.American journal of cancer research · 2025Article
- Interventional oncology and immunotherapy: current status and future perspectives.Frontiers in immunology · 2025Review
- Maintenance treatment of immunotherapy after microwave ablation plus drug-eluting bead bronchial arterial chemoembolization for advanced non-small cell lung cancer: a retrospective single-center cohort study.Quantitative imaging in medicine and surgery · 2024Article
- Acute-phase plasma proteomics of rabbit lung VX2 tumors treated by image-guided microwave ablation.Frontiers in oncology · 2024Article
- Retrospective cohort study on the correlation analysis among peri-procedural factors, complications, and local tumor progression of lung tumors treated with CT-guided microwave ablation.Journal of thoracic disease · 2023Article
- Percutaneous core-needle biopsy before and immediately after coaxial microwave ablation in solid non-small cell lung cancer: the comparison of genomic testing from specimens.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Review
- [Current Treatment Status and Prospect of Surgery and Thermal Ablation for Pulmonary Oligometastases in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 18 institutions in 1 country.
Funding
Abstract
objectivesThis prospective trial was performed to verify whether microwave ablation (MWA) in combination with chemotherapy could provide superior survival benefit compared with chemotherapy alone. MATERIALS AND
methodsFrom March 1, 2015, to June 20, 2017, treatment-naïve patients with pathologically verified advanced or recurrent non-small cell lung cancer (NSCLC) were randomly assigned to MWA plus chemotherapy group or chemotherapy group. The primary endpoint was progression-free survival (PFS), while the secondary endpoints included overall survival (OS), time to local progression (TTLP), and objective response rate (ORR). The complications and adverse events were also reported.
resultsA total of 293 patients were randomly assigned into the two groups. One hundred forty-eight patients with 117 stage IV tumors were included in the MWA plus chemotherapy group. One hundred forty-five patients with 113 stage IV tumors were included in the chemotherapy group. The median follow-up period was 13.1 months and 12.4 months, respectively. Median PFS was 10.3 months (95% CI 8.0-13.0) in the MWA plus chemotherapy group and 4.9 months (95% CI 4.2-5.7) in the chemotherapy group (HR = 0.44, 95% CI 0.28-0.53; p < 0.0001). Median OS was not reached in the MWA plus chemotherapy group and 12.6 months (95% CI 10.6-14.6) in the chemotherapy group (HR = 0.38, 95% CI 0.27-0.53; p < 0.0001) using Kaplan-Meier analyses with log-rank test. The median TTLP was 24.5 months, and the ORR was 32% in both groups. The adverse event rate was not significantly different in the two groups.
conclusionsIn patients with advanced NSCLC, longer PFS and OS can be achieved with the treatment of combined MWA and chemotherapy than chemotherapy alone. KEY POINTS: • Patients treated with MWA plus chemotherapy had superior PFS and OS over those treated with chemotherapy alone. • The ORR of patients treated with MWA plus chemotherapy was similar to that of those treated with chemotherapy alone. • Complications associated with MWA were common but tolerable and manageable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.